| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1370 | |
| Phytochemical name or plant extracts | Melaleuca Alternifolia Concentrate | |
| PMID | 34119930 | |
| Literature evidence | The antitumor activity of the tea tree oil (TTO) derived product, Melaleuca Alternifolia Concentrate (MAC) was characterized mechanistically at the molecular and cellular level. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | NA | |
| Source of phytochemicals or plant Extracts | Melaleuca Alternifolia | |
| Geographical availability | New South Wales, Queensland | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Prostate cancer | |
| Target gene or protein | Caspase 3, Caspase 7 | |
| Gene or Protein evidence | Involving increased mitochondrial superoxide production, loss of mitochondrial membrane potential (MMP), caspase 3/7 activation, as well as the presence of TUNEL+ and cleaved-PARP+ cell populations. | |
| Target pathways | Mitochondrial apoptotic pathway | |
| IC50 | At 24h, 48h, 72h: 0.085 (±?0.023) % v/v, 0.057 (±?0.013) % v/v, 0.057 (±?0.016) % v/v against MCF-7 respectively | |
| Potency | NA | |
| Cell line/ mice model | MCF-7, LNCaP | |
| Additional information | At concentrations of 0.01-0.04% v/v, MAC caused cell cycle arrest in the G0/1-phase, as well as autophagy | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:597833-1 | |
| Safety | NA |